What type of study is this?

This is a Human Clinical Trial study.

October 3, 2025Clinical ChemistryOpen Access

A-389 Development of a Sensitive Lateral Flow Immunoassay for Simultaneous Detection of GFAP, FABP, and UCH-L1 in Mild Traumatic Brain Injury Management

View Full Paper

Ask AI

Bookmark

The assay reveals high sensitivity and specificity for detecting mild traumatic brain injury biomarkers.
It achieves detection limits of 24.5 pg/mL for GFAP, 120 pg/mL for FABP, and 92 pg/mL for UCH-L1.
Employing a time-resolved fluorescence-based system enhances both sensitivity and reproducibility.
The platform may reduce diagnostic time and medical costs, enabling timely intervention for patients.

Authors

No takes yet. Share an insight, caveat, or question.

Development of a lateral flow immunoassay detects GFAP, FABP, and UCH-L1 in mild TBI, suggesting improved diagnostics.

H Y Kim (2025) studied this question.

View Full Paper

Ask AI

Bookmark